Skip to main content
Click Here For COVID-19 Studies
Home
Clinical Trials Office Register as a Researcher Log In
348 Studies Now Enrolling
 Menu
Home How It Works Resources Join RecruitMe

Search

Reset

Status

  • Currently Recruiting (1)
  • Closed (3)

Medical Condition

  • Show all (94)
  • Autoimmune Disorders (4)
  • Blood Disorders (2)
  • Bone & Muscle (1)
  • Cancer (52)
    • Breast Cancer (1)
    • Kidney Cancer (8)
    • Leukemia (1)
    • Sarcoma (1)
    • Skin Cancer (1)
    • (-) Solid Tumors (3)
  • COVID-19 (Coronavirus) (1)
  • Diabetes (1)
  • Healthy Volunteers (1)
  • Heart Disease (3)
  • Kidney Disease (12)
  • Liver Disease (2)
  • Lung Disease (1)
  • Neurological Disorders (1)
  • (-) Obesity (1)
  • Surgery (1)
  • Transplant (10)
  • Vascular Conditions (1)
Displaying 1 - 4 of 4

POWERS - Understanding Body Changes After Weight Loss

Condition: Obesity
Investigator: Rudolph Leibel, MD
Status: Currently Recruiting
The Physiology of the Weight Reduced State (POWERS) is a national research study designed to discover and learn what happens to the human body after weight loss and to learn why some people regain their lost weight. Understanding why this happens could help health professionals improve strategies for successful weight loss maintenance after weight loss.…
Read More

Study of XmAb22841 Monotherapy and in Combination with Pembrolizumab in Subjects with Selected Advanced Solid Tumors (DUET-4)

Condition: Cancer / Solid Tumors
Investigator: Mark Stein, MD
Status: Closed
The primary purpose of this research study is to learn the safety and tolerability of the investigational drug, XmAb 22841 when given alone or in combination with another drug called pembrolizumab. You will be assigned to either receive XmAb22841 alone or in combination with pembrolizumab and you will know what treatment you are receiving. This study will…
Read More

A Study of JNJ-63898081 in Participants With Advanced Stage Solid Tumors

Condition: Cancer / Solid Tumors
Investigator: Emerson Lim, MD
Status: Closed
The purpose of this study is to find a safe dose of JNJ-63898081 that can be used for further studies in subjects with advanced cancers such as metastatic castration resistant prostate cancer (mCRPC) or metastatic kidney cancer, also referred to as renal cell carcinoma. This is a Phase 1 study and the first time JNJ-63898081…
Read More

Study of TSR-042 (anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

Condition: Cancer / Solid Tumors
Investigator: June Hou, MD
Status: Closed
The study drug (TSR-042) in this study is designed to stop cancer from growing by helping your immune system recognize and fight the cancer. The Study Drug is designed to help your immune system by attaching to a protein called PD-1 and stopping one of the signals that keeps your immune system from recognizing the cancer. This may help your immune system…
Read More
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE
COMPLIANCE
Compliance Hotline Compliance Program
RESOURCES
Contact RecruitMe Terms of Use Privacy Policy ©2025 Columbia University
SCHOOLS
Vagelos College of Physicians and Surgeons Mailman School of Public Health School of Nursing College of Dental Medicine Graduate School of Arts and Science